Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr. Busenbark has more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. During a 23 year career at Baxter Healthcare, Mr. Busenbark held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. This included roles as Chief Financial Officer of Immuno AG when the company was acquired by Baxter, and President of Baxter's global Plasma Therapeutics business. Mr. Busenbark's most recent role was as Chief Financial Officer at Encysive Pharmaceuticals, where his accomplishments included raising more than $100 million in debt and equity financing.

"We are very pleased to have Gordon join Xytis," said Vincent F. Simmon, CEO and President. "He brings great financial and operational experience, both from a large pharmaceutical company perspective as well as from that of a smaller biotechnology company. Gordon joins us at an exciting time for Xytis. Our Phase 2 clinical trial in Traumatic Brain Injury (TBI) is approximately half way enrolled. Also, there is considerable partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine receptors. His experience and assistance in financing and marshalling these programs forward will be greatly welcomed."

Mr. Busenbark has both a B.S. in Accounting and an MBA from the University of Utah.

About Xytis

Xytis Inc. is a privately held discovery and development biopharmaceutical company, headquartered in Irvine, California, and having a clinical development group in Nyon, Switzerland, focused on innovative CNS drug candidates. The Company's investors include Atlas Venture, Sanderling Ventures, CDC Innovation, and Ventech. Xytis has a rich portfolio of proprietary preclinical compounds that are novel, highly selective allosteric modulators of nicotinic acetylcholine receptors (nAChRs), GABA-A receptors and other well-validated CNS targets. The Company has two compounds in clinical development -- Neboglamine (XY2401) and Anatibant (XY2405). Neboglamine is a selective norepinephrine uptake inhibitor, which has completed single and multiple dose Phase 1 studies, and is intended for the treatment of patients with schizophrenia and/or major depression. XY2401 has been well tolerated in the Phase 1 studies. Anatibant (XY2405), Xytis' lead compound, is under development for TBI with a Phase 2 multi-center trial ongoing in nine countries worldwide with more than 200 patients enrolled. See http://www.xytis.com for additional information.


'/>"/>
SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... Application, Usability - Forecast to 2025" report to their offering. ... , , ... grow at a CAGR of around 3.2% from 2015 to 2025. ... advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... 08, 2016 , ... Launching of the ... Instance Manager architecture, meeting the needs of multichannel growth and doubling the ... auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative flexibility ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
Breaking Medicine News(10 mins):